Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Mantle cell lymphoma diagnostic study of choice
Introduction
Overview
Overview
Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.
Diagnostic Study of Choice
Diagnostic Study of Choice
Study of choice
- Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.
Histology
- The microscopic histological findings can be found here.
Immunohistochemistry
- CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 are usually negative.[1][2]
- Cyclin D1 is positive in majority of the cases.
- SOX11 expression is useful if cyclin D1 is negative.
- Ki-67 should also be included in the initial work-up. Ki-67 proliferation index of less than 30% is associated with a favorable prognosis.[3][4]
Fluorescence in situ hybridization (FISH)
- FISH can be used to detect the translocation t(11;14), which is found in most of MCL patients.[5]
Karyotyping:
- Karyotyping can also be used to detect the translocation t(11;14), which is found in most of MCL patients.[6]
References
References
- ↑ Francesco Bertoni, Emanuele Zucca & Finbarr E. Cotter (2004). “Molecular basis of mantle cell lymphoma”. British journal of haematology. 124 (2): 130–140. PMID 14687022. Unknown parameter
|month=ignored (help) - ↑ Chan Yoon Cheah, John F. Seymour & Michael L. Wang (2016). “Mantle Cell Lymphoma”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34 (11): 1256–1269. doi:10.1200/JCO.2015.63.5904. PMID 26755518. Unknown parameter
|month=ignored (help) - ↑ Olaf Determann, Eva Hoster, German Ott, Heinz Wolfram Bernd, Christoph Loddenkemper, Martin Leo Hansmann, Thomas E. F. Barth, Michael Unterhalt, Wolfgang Hiddemann, Martin Dreyling & Wolfram Klapper (2008). “Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group”. Blood. 111 (4): 2385–2387. doi:10.1182/blood-2007-10-117010. PMID 18077791. Unknown parameter
|month=ignored (help) - ↑ R. Schaffel, C. V. Hedvat, J. Teruya-Feldstein, D. Persky, J. Maragulia, D. Lin, C. S. Portlock, C. H. Moskowitz & A. D. Zelenetz (2010). “Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma”. Annals of oncology : official journal of the European Society for Medical Oncology. 21 (1): 133–139. doi:10.1093/annonc/mdp495. PMID 20019090. Unknown parameter
|month=ignored (help) - ↑ Tsieh Sun, Mary Lowery Nordberg, James D. Cotelingam, Diana M. Veillon & John Ryder (2003). “Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma”. American journal of hematology. 74 (1): 78–84. doi:10.1002/ajh.10356. PMID 12949897. Unknown parameter
|month=ignored (help) - ↑ Jordi Camps, Itziar Salaverria, Maria J. Garcia, Esther Prat, Silvia Bea, Jessica C. Pole, Lluis Hernandez, Javier Del Rey, Juan Cruz Cigudosa, Marta Bernues, Carlos Caldas, Dolors Colomer, Rosa Miro & Elias Campo (2006). “Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines”. Leukemia research. 30 (8): 923–934. doi:10.1016/j.leukres.2005.11.013. PMID 16448697. Unknown parameter
|month=ignored (help)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]